Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3529]

Ceritinib may receive conditional marketing authorisation for non-small cell lung cancer

Ceritinib may receive conditional marketing authorisation for non-small cell lung cancer

Carfilzomib outperforms bortezomib in patients with relapsed multiple myeloma

Carfilzomib outperforms bortezomib in patients with relapsed multiple myeloma

FDA grants approval to nivolumab for non-small cell lung cancer

FDA grants approval to nivolumab for non-small cell lung cancer

New breast cancer test links immune ‘hotspots’ to better survival

New breast cancer test links immune ‘hotspots’ to better survival

FDA approves panobinostat for multiple myeloma

FDA approves panobinostat for multiple myeloma

ASCO GU: Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

ASCO GU: Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

Launch of the Immuno-Oncology Policy Action Framework

Launch of the Immuno-Oncology Policy Action Framework

Meeting report from the second EurocanPlatform summer school on translational cancer research published in ecancermedicalscience

Meeting report from the second EurocanPlatform summer school on translational cancer research published in...

DNA-damage causes immune reaction and inflammation and is linked to cancer development

DNA-damage causes immune reaction and inflammation and is linked to cancer development

$FDA approves lenvatinib for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer$

FDA approves lenvatinib for locally recurrent or metastatic, progressive, radioactive iodine-refractory...

More from ecancer